Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume

11 dicembre 2017 aggiornato da: Johanna Savilampi, Region Örebro County

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers

The purpose of the study is to evaluate the impact of different bolus volumes and viscosity on remifentanil-induced swallowing dysfunction in healthy volunteers.Hence, whether swallowing tasks can be done safer during sedation by altering bolus volumes and viscosities will be revealed. Furthermore, the study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. If methylnaltrexone reverses the remifentanil-induced effects on swallowing, this would suggest a dominant peripherally mediated mechanism.

Panoramica dello studio

Descrizione dettagliata

Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.

Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.

The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.

20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

20

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 40 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. ≥ 18 - ≤ 40 year old healthy volunteers from both sexes.
  2. Have signed and dated Informed Consent.
  3. Willing and able to comply with the protocol for the duration of the trial.

Exclusion Criteria:

  1. Anamnesis of pharyngoesophageal dysfunction.
  2. Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease
  3. Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway.
  4. Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine.
  5. Pregnancy or breast feeding
  6. BMI > 30
  7. Smoking
  8. Previous participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: RemifentanilMNTX
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Altri nomi:
  • Ultiva
  • Relistor
  • Remifentanil
  • Metilnaltrexone
Comparatore attivo: PlaceboMNTX
Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Altri nomi:
  • Cloruro di sodio 0,9%
  • Relistor
  • Metilnaltrexone

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
Lasso di tempo: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
Up to 60 minutes

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
Lasso di tempo: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
Up to 60 minutes
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
Lasso di tempo: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
Lasso di tempo: Up to 60 minutes
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
Lasso di tempo: Up to 60 minutes
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
Lasso di tempo: Up to 60 minutes
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
Lasso di tempo: Up to 60 minutes
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
Lasso di tempo: Up to 60 minutes
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Johanna Savilampi, MD, PhD, University Hospital in Örebro

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 novembre 2017

Completamento primario (Anticipato)

1 aprile 2018

Completamento dello studio (Anticipato)

1 aprile 2018

Date di iscrizione allo studio

Primo inviato

12 settembre 2017

Primo inviato che soddisfa i criteri di controllo qualità

12 settembre 2017

Primo Inserito (Effettivo)

14 settembre 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 dicembre 2017

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 dicembre 2017

Ultimo verificato

1 dicembre 2017

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi